Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Octagon Capital Advisors sold 470,000 shares of Dianthus Therapeutics in the first quarter, an estimated $27.22 million transaction based on quarterly average prices. The filing is a notable ownership/flow update but does not indicate a change in fundamentals or guidance. Market impact is likely limited unless followed by additional selling or new company-specific news.

Analysis

Octagon Capital Advisors sold 470,000 shares of Dianthus Therapeutics in the first quarter, an estimated $27.22 million transaction based on quarterly average prices. The filing is a notable ownership/flow update but does not indicate a change in fundamentals or guidance. Market impact is likely limited unless followed by additional selling or new company-specific news.